JP Morgan Cazenove covered GlaxoSmithKline PLC (LON:GSK), renewing its price target at 1,900.00GBX earlier today
- Updated: September 18, 2016
Indicating a possible upside of 0.12%, JP Morgan Cazenove held the estimated target of GlaxoSmithKline PLC (LON:GSK) at 1,900GBX.
On 8/12/2016, JP Morgan Cazenove released a statement on GlaxoSmithKline PLC(LON:GSK) raised the target price from 1,800.00GBX to 1,900.00GBX that indicated a possible upside of 0.13%.
Displaying a price of 1,697.50GBX, GlaxoSmithKline PLC (LON:GSK) traded 0.49% lower on the day. With the last stock price close up 5.98% from the two hundred day average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the same time. GSK has registered a 50-day moving average of 1,658.43GBX and two hundred day moving average of 1,524.87GBX. 13,339,146 shares of GSK traded, up from ann average volume of 8,806,050
See Graphic Below:
GlaxoSmithKline PLC has a PE of 2,693 with a 52 week low of 1,227.50GBX and a one-year high of 1,716.50GBX. GlaxoSmithKline PLC’s market cap is presently 0.0 GBX.
A total of 24 firms have issued a ratings update on the company. Three analysts rate the stock a strong buy, six firms rate the company a buy, 17 firms rate the stock a hold, two firms rate the company to underperform, and finally 0 brokeragesrate the company as sell with a 12-month target price of 1,577.33GBX
General Company Details For GlaxoSmithKline PLC (LON:GSK)
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, and respiratory and rare diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.